<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 21, 2025</title>
<meta name="color-scheme" content="light" />
<style>
  :root { --maxw: 800px; color-scheme: light; }
  html { -webkit-text-size-adjust: 100%; }
  body {
    margin: 0;
    padding: 0;
    background-color: #ffffff;
    color: #111111;
    font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji;
    line-height: 1.6;
    font-size: 18px;
  }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

La <span title="chronic kidney disease">enfermedad renal crónica</span> (ERC) ahora <span title="is classified">se clasifica</span> según el <span title="glomerular filtration rate (GFR)">FG</span> y la <span title="albumin in urine">albuminuria</span>. El <span title="cardiovascular risk">riesgo cardiovascular</span> <span title="is very important">es muy importante</span> para el <span title="prognosis">pronóstico</span>. La <span title="clinical practice guideline">guía de práctica clínica</span> KDIGO 2024 para ERC <span title="recommends using">recomienda usar</span> <span title="SGLT2 inhibitors">inhibidores de SGLT2</span> (iSGLT2) y <span title="GLP-1 receptor agonists">agonistas del receptor GLP-1</span> (aGLP-1) en <span title="more patients with CKD">más pacientes con ERC</span>, <span title="not only">no solo</span> en la <span title="overt diabetic nephropathy">nefropatía diabética manifiesta</span>.

KDIGO 2024 <span title="recommends SGLT2 inhibitors">recomienda iSGLT2</span> en <span title="adults with CKD and diabetes">adultos con ERC y diabetes</span>, y también en <span title="non-diabetic CKD">ERC no diabética</span>, <span title="when the estimated GFR is">cuando el FG estimado es</span> ≥20 mL/min/1.73 m² y la <span title="albuminuria is at least">albuminuria es ≥30 mg/g</span>. <span title="This is based mainly on">Esto se basa principalmente en</span> los <span title="DAPA-CKD and EMPA-KIDNEY studies">estudios DAPA-CKD y EMPA-KIDNEY</span>.

Los iSGLT2 <span title="are a key therapy">son una terapia clave</span> para la <span title="renal and cardiovascular protection">protección renal y cardiovascular</span> en la <span title="type 2 diabetes with CKD">diabetes tipo 2 con ERC</span>, <span title="in addition to">además del</span> <span title="renin-angiotensin-aldosterone system blockade">bloqueo del sistema renina-angiotensina-aldosterona</span> (SRAA) a la <span title="maximum tolerated dose">dosis máxima tolerada</span> <span title="when necessary">cuando sea necesario</span>. <span title="Start SGLT2 inhibitors">Inicie los iSGLT2</span> a las <span title="usual doses">dosis habituales</span> (empagliflozina 10 mg, dapagliflozina 10 mg diarios). <span title="Continue until dialysis or kidney replacement">Continúe hasta diálisis o reemplazo renal</span>, <span title="unless not tolerated">a menos que no se tolere</span>.

Una <span title="small early decrease in GFR">pequeña disminución temprana del FG</span> (≤30%) <span title="is common">es común</span> y <span title="is usually hemodynamic">suele ser hemodinámica</span>. <span title="Do not stop">No suspenda</span> si el <span title="patient is stable">paciente está estable</span>.

Los aGLP-1 <span title="with cardiovascular benefit">con beneficio cardiovascular</span> (semaglutida, liraglutida) <span title="are the next option">son la siguiente opción</span> <span title="after SGLT2 inhibitors">después de los iSGLT2</span> en <span title="type 2 diabetes with CKD">diabetes tipo 2 con ERC</span>.

<span title="Try to combine">Intente combinar</span> el <span title="RAAS blockade">bloqueo del SRAA</span>, iSGLT2 y aGLP-1 <span title="when possible">cuando sea posible</span>. Para <span title="non-diabetic CKD with albuminuria">ERC no diabética con albuminuria</span>, <span title="use SGLT2 inhibitors plus RAAS blockade">use iSGLT2 más bloqueo del SRAA</span>, y <span title="consider GLP-1 agonists">considere aGLP-1</span> para <span title="obesity and cardiometabolic risk">obesidad y riesgo cardiometabólico</span>.

---
DIALOGUE

Narrator: Hoy, el Dr. Kumar <span title="talks with Mr. Lee">habla con el Sr. Lee</span> <span title="about his kidney disease">sobre su enfermedad renal</span>.
Physician: Hola, Sr. Lee. <span title="Your tests show">Sus análisis muestran</span> que <span title="you have chronic kidney disease">tiene enfermedad renal crónica</span>, o ERC.
Patient: <span title="Is that very serious">¿Eso es muy grave</span>? <span title="What does it mean">¿Qué significa</span>?
Physician: ERC <span title="means that">significa que</span> sus <span title="kidneys are not working as they should">riñones no están funcionando como deberían</span>. <span title="We assess this with">Evaluamos esto con</span> dos cosas: el FG y la <span title="albumin in your urine">albúmina en su orina</span>.
Patient: <span title="Can my kidneys get better">¿Mis riñones pueden mejorar</span>?
Physician: <span title="We cannot cure CKD">No podemos curar la ERC</span>, <span title="but we can protect your kidneys">pero sí podemos proteger sus riñones</span>. <span title="I want to start">Quiero comenzar</span> un <span title="medicine called SGLT2 inhibitor">medicamento llamado inhibidor de SGLT2</span>.
Patient: <span title="Is that for diabetes">¿Eso es para la diabetes</span>? <span title="I do not have diabetes">Yo no tengo diabetes</span>.
Physician: Sí, <span title="but new studies show">pero nuevos estudios muestran</span> que los <span title="SGLT2 inhibitors help even without diabetes">inhibidores de SGLT2 ayudan incluso sin diabetes</span>, <span title="if you have albumin in the urine and GFR over 20">si tiene albúmina en la orina y FG mayor de 20</span>.
Patient: <span title="Will I have side effects">¿Tendré efectos secundarios</span>?
Physician: <span title="You may notice">Puede notar</span> una <span title="decrease in GFR">disminución del FG</span> en las <span title="first weeks">primeras semanas</span>. <span title="This is normal and safe">Esto es normal y seguro</span> <span title="if you feel well">si se siente bien</span>.
Patient: <span title="Do I need other medicines">¿Necesito otros medicamentos</span>?
Physician: Sí. <span title="We will keep your other medicines">Mantendremos sus otros medicamentos</span>, <span title="such as RAAS blockers">como los bloqueadores del SRAA</span>, y <span title="we might add another called">podríamos agregar otro llamado</span> <span title="GLP-1 receptor agonist">agonista del receptor GLP-1</span> <span title="if you need it">si lo necesita</span>.
Patient: <span title="Will I need dialysis">¿Necesitaré diálisis</span>?
Physician: <span title="We hope that">Esperamos que</span> estos <span title="medicines slow kidney damage">medicamentos ralenticen el daño renal</span>. <span title="You may not need dialysis for a long time">Puede que no necesite diálisis por mucho tiempo</span>.
    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Chronic kidney disease (CKD) is now staged by both GFR and albuminuria. Cardiovascular risk is very important for prognosis. KDIGO 2024 clinical practice guideline for CKD says to use SGLT2 inhibitors (SGLT2i) and GLP‑1 receptor agonists (GLP‑1RA) in more CKD patients, not only in overt diabetic nephropathy.

KDIGO 2024 recommends SGLT2i in adults with CKD and diabetes, and also in non‑diabetic CKD, when eGFR is ≥20 mL/min/1.73 m² and albuminuria is ≥30 mg/g. This is based mainly on DAPA‑CKD and EMPA‑KIDNEY.

SGLT2i are key kidney‑ and cardio‑protective therapy in T2D with CKD, on top of maximally tolerated RAAS blockade when needed. Start SGLT2i at usual doses (empagliflozin 10 mg, dapagliflozin 10 mg daily). Keep going until dialysis or kidney replacement, unless not tolerated.

A small early eGFR dip (≤30%) is common and is usually hemodynamic. Do not stop if the patient is stable.

GLP‑1RA with cardiovascular benefit (semaglutide, liraglutide) are the next choice after SGLT2i in T2D with CKD.

Try to combine RAAS blockade, SGLT2i, and GLP‑1RA when you can. For non‑diabetic CKD with albuminuria, use SGLT2i plus RAAS blockade, and think about GLP‑1RA for obesity and cardiometabolic risk.

---
DIALOGUE

Narrator: Today, Dr. Kumar talks with Mr. Lee about his kidney disease.
Physician: Hello, Mr. Lee. Your lab tests show you have chronic kidney disease, or CKD.
Patient: Is that very bad? What does it mean?
Physician: CKD means your kidneys are not working as they should. We check this with two things: GFR and albumin in your urine.
Patient: Can my kidneys get better?
Physician: We cannot cure CKD, but we can protect your kidneys. I want to start you on a medicine called SGLT2 inhibitor.
Patient: Is that for diabetes? I do not have diabetes.
Physician: Yes, but new studies show SGLT2 inhibitors help even without diabetes, if you have albumin in your urine and GFR over 20.
Patient: Will I have side effects?
Physician: You may see a drop in GFR in the first weeks. This is normal and safe if you feel well.
Patient: Do I need other medicines?
Physician: Yes. We will keep your other medicines, like RAAS blockers, and may add another called GLP-1 receptor agonist if you need it.
Patient: Will I need dialysis?
Physician: We hope these medicines slow kidney damage. You may not need dialysis for a long time.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 21, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>